Clinical Scorecard: Combining Aromatase Inhibitors with Growth Hormone Therapy for Male Adolescents with Idiopathic Short Stature - Correction Summary
At a Glance
Category
Detail
Condition
Idiopathic Short Stature in Male Adolescents
Key Mechanisms
Use of Aromatase Inhibitors combined with Growth Hormone Therapy
Target Population
Male adolescents with idiopathic short stature
Care Setting
Clinical endocrinology treatment settings
Key Highlights
Correction of adverse event data related to sleep and mental symptoms during treatment.
Updated incidence of joint pain symptoms in treatment groups.
Clarification of patient-reported side effects in combined Aromatase Inhibitors (AIs) and GnRHa treatment groups.
Guideline-Based Recommendations
Diagnosis
Assess idiopathic short stature in male adolescents prior to therapy initiation.
Management
Consider combined Aromatase Inhibitors and Growth Hormone therapy for eligible patients.
Monitor for sleep problems, mental symptoms, and joint pain during treatment.
Monitoring & Follow-up
Regularly evaluate patients for adverse effects including drowsiness, difficulty falling asleep, memory loss, anxiety, and joint pain.
Differentiate symptom incidence between combined AIs and GnRHa treatment groups.
Risks
Potential for sleep disturbances and mental symptoms in a minority of patients.
Joint pain reported more frequently in combined AIs treatment group compared to GnRHa group.
Patient & Prescribing Data
Male adolescents undergoing combined Aromatase Inhibitors and Growth Hormone therapy
2 children reported sleep problems; 9 children reported mental symptoms; 11 children experienced joint pain (8 in combined AIs group, 3 in combined GnRHa group).
Clinical Best Practices
Accurately document and monitor adverse events during therapy.
Inform patients and caregivers about possible side effects including sleep and mental symptoms and joint pain.
Adjust treatment plans based on patient tolerance and reported symptoms.
